- Companies
- IMBdx
IMBdx Valuation Multiples
IMBdx is valued at $31M as of October 2026, a 4.5x revenue multiple. In the last fiscal year, IMBdx revenue was $4M and IMBdx EBITDA was ($5M).
IMBdx Overview
About IMBdx
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.
Founded
2018
HQ
Employees
N/A
Website
Financials (Last FY)
EV
$18M
Valuation Multiples
Start free trialIMBdx Financials
IMBdx reported last fiscal year revenue of $4M and negative EBITDA of ($5M).
In the same fiscal year, IMBdx generated $1M in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).
IMBdx P&L
In the most recent fiscal year, IMBdx reported revenue of $4M and EBITDA of ($5M).
IMBdx is unprofitable as of last fiscal year, with gross margin of 26%, EBITDA margin of (134%), and net margin of (149%).
Financial data powered by Morningstar, Inc.
IMBdx Stock Performance
IMBdx has current market cap of $31M, and enterprise value of $18M.
Market Cap Evolution
IMBdx's stock price is $2.14.
IMBdx share price decreased by 0.5% in the last 30 days.
IMBdx has an EPS (earnings per share) of $-0.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18M | $31M | 0.0% | -0.5% | - | - | $-0.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIMBdx Valuation Multiples
IMBdx trades at 4.5x EV/Revenue multiple, and (3.4x) EV/EBITDA.
IMBdx Financial Valuation Multiples
As of October 5, 2026, IMBdx has market cap of $31M and EV of $18M.
IMBdx has a P/E ratio of (5.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IMBdx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


IMBdx Margins & Growth Rates
In the most recent fiscal year, IMBdx reported gross margin of 26%, EBITDA margin of (134%), and net margin of (149%).
IMBdx Margins
IMBdx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
IMBdx Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
IMBdx Competitors
IMBdx competitors include Ortoma, Q-linea, iTonic Holdings, InspireMD, Anatolia Geneworks, aap Implantate, Nortech Systems, CleanSpace Holdings, Sernova Biotherapeutics and Mauna Kea Technologies.
Most IMBdx public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $6M | ($470K) | 3.9x | 3.7x | (54.0x) | (9.6x) | |||
| $1M | ($16M) | 13.3x | - | (0.9x) | - | |||
| $523K | ($5M) | 54.0x | - | (5.6x) | - | |||
| $9M | ($49M) | 0.2x | 0.2x | (0.0x) | (0.0x) | |||
| $15M | ($2M) | 2.8x | - | (19.0x) | - | |||
| $14M | ($893K) | 2.3x | 2.6x | (36.7x) | (14.4x) | |||
| $118M | $2M | 0.4x | - | 22.0x | - | |||
| $14M | ($250K) | 1.6x | 1.5x | (87.7x) | 302.7x | |||
This data is available for Pro users. Sign up to see all IMBdx competitors and their valuation data. Start Free Trial | ||||||||
IMBdx VC Funding History
Before going public, IMBdx raised $28M in total equity funding, across 3 rounds.
IMBdx Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IMBdx
| When was IMBdx founded? | IMBdx was founded in 2018. |
| Where is IMBdx headquartered? | IMBdx is headquartered in South Korea. |
| Is IMBdx publicly listed? | Yes, IMBdx is a public company listed on Korea Exchange. |
| What is the stock symbol of IMBdx? | IMBdx trades under 461030 ticker. |
| When did IMBdx go public? | IMBdx went public in 2024. |
| Who are competitors of IMBdx? | IMBdx main competitors include Ortoma, Q-linea, iTonic Holdings, InspireMD, Anatolia Geneworks, aap Implantate, Nortech Systems, CleanSpace Holdings, Sernova Biotherapeutics, Mauna Kea Technologies. |
| What is the current market cap of IMBdx? | IMBdx's current market cap is $31M. |
| What is the current revenue of IMBdx? | IMBdx's last fiscal year revenue is $4M. |
| What is the current EV/Revenue multiple of IMBdx? | Current revenue multiple of IMBdx is 4.5x. |
| Is IMBdx profitable? | No, IMBdx is not profitable. |
| How many companies IMBdx has acquired to date? | IMBdx hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies IMBdx has invested to date? | IMBdx hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to IMBdx
Lists including IMBdx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




